Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06055543
Other study ID # Fortimel PlantBased Spain 2022
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date August 9, 2023
Est. completion date May 31, 2024

Study information

Verified date September 2023
Source Danone Specialized Nutrition
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to compare nutritional outcomes in terms of percentage of weight gain between a new planted-based high-energy ONS and a standard high-energy ONS with animal protein (cow's mil protein) in patients at malnutrition according to Global Leadership Initiative on Malnutrition (GLIM) criteria.


Description:

Due to the increasingly pressing need to develop an oral nutritional supplement (ONS) that does not contain animal ingredients, Fortimel PlantBased, suitable for patients with Disease-Related Malnutrition or who wish to avoid or reduce the consumption of animal products for dietary or lifestyle reasons, is being promoted. At the same time, it is also a therapeutic option to be considered in the population with allergy or intolerance to cow's milk protein. Therefore, the aim is to offer an adapted therapeutic nutritional solution that guarantees nutritional results that are not inferior than ONS with animal protein (cow's milk protein). This study was designed as an open-label randomized controlled non-inferiority trial with two arms: a new planted-based ONS (Fortimel PlantBased) as the intervention arm and standard ONS (Fortimel Energy) as the control arm, both high-energy formulas (1.5 kcal/m; 200ml). The study will be carried out in patients at malnutrition according to Global Leadership Initiative on Malnutrition (GLIM) criteria, who need to supplement their diet by taking a high-energy ONS for at least 12 weeks. These patients will be treated and follow-up by the Endocrinology and Nutrition services of 6 public hospitals in Spain.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date May 31, 2024
Est. primary completion date May 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients = 18 years old - Malnourished patients according to GLIM criteria - Patients with a high energy requirement (1.5kcal/ml) requiring the intake of 2 bottles of ONS per day for at least 12 weeks - Patients presenting any of the following clinical situations: - Elderly patients requiring oral nutritional support - Patients with digestive pathology including but not restricted to inflammatory bowel disease, short bowel syndrome, pancreatitis, without active malabsorption and maldigestion. - Chronic diseases such as COPD, mild to moderate renal disease, HIV - Oncologic patients with Eastern Cooperative Oncology Group (ECOG) 0-1 - Patients who have given their consent to participate - Patients who, in the opinion of the physician, have the capacity to answer the study questionnaires themselves or their caregivers Exclusion Criteria: - Patients who need ONS due to surgical or acute illness* - Patients with known intolerance or allergy to cow's milk, soya or peas - Patients with hyperthyroidism. Patients with uncontrolled hypothyroidism - Uncontrolled diabetic patients (HbA1c >8%) - Patients requiring enteral nutrition by tube or ostomy - Patients with moderate and serious renal insufficiency < 30ml/min/1,73 m2 - Patients who have value creatinine: - 1,70 mg/dl - 150,31umol/L Men - 1,50 mg/dl - 132,63umol/L Women - Patients with levels of haemoglobin <10 g/dl, transferrin <150 mg /dl

Study Design


Intervention

Dietary Supplement:
Fortimel
2 bottles/day of the high energy ONS

Locations

Country Name City State
Spain Hospital Universitario de Basurto Bilbao
Spain Hospital Universitario Reina Sofía Córdoba
Spain Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria
Spain Hospital Universitario de Móstoles Madrid
Spain Hospital Universitario Virgen del Rocío Sevilla
Spain Hospital Clínico Valladolid Valladolid

Sponsors (1)

Lead Sponsor Collaborator
Danone Specialized Nutrition

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in weight Change in weight percentage Changes between baseline and final visit (12 weeks).
Primary Improvement in nutritional status Improvement in nutritional status according to the GLIM criteria. A change in classification category from grade 2 of malnutrition to grade 1 or not meet GLIM criteria, as well as a change from grade 1 to not meet GLIM criteria are considered an improvement. From the baseline to the final visit (12 weeks)
Secondary Change in muscle strength Measured by dynamometry From the baseline to final visit (12 weeks)
Secondary Change in calf circumference From baseline to final visit (12 week)
Secondary Percentage of compliance Taking into account the number of bottles per day taken, the ml of product and the ml left over. During the study follow up
Secondary Changes in the gastrointestinal symptom scale (GSRS) Total score From the baseline to final visit (12 week)
Secondary ONS Satisfaction Patients satisfaction taking ONS will be considered if a patient indicates a score of at least 8 points for overall satisfaction question. Final visit (12 week)
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients